@entity5344 incidence after XXXX and in vitro fertilisation.

@entity43 @entity1 @entity249 @entity5344 @entity0 @entity4093 @entity5 @entity52
Concern has been expressed that exposure to fertility drugs might be associated with a risk of @entity43 . We have examined the incidence of @entity5344 in a cohort of 10,358 @entity1 referred for @entity52 ( @entity52 ) treatment in Victoria, Australia, between 1978 and 1992. The "exposed" group (n = 5564) had had ovarian stimulation to induce multiple folliculogenesis and the "unexposed" group (n = 4794) had been referred for @entity52 but were untreated or had had "natural cycle" treatment without ovarian stimulation. Duration of follow-up ranged from 1 to 15 years. Cases of @entity5 were determined by record linkage with data from population-based @entity5 registries. 34 cases of @entity0 and 6 of invasive @entity43 were observed. A comparison with the expected numbers, derived by applying age-standardised general population rates to the cohort gave standardised incidence ratios (SIR) for @entity0 of 0.89 (95% CI 0.55-1.46) in the exposed group and 0.98 (0.62-1.56) in the unexposed group, and for @entity43 SIRs were 1.70 (0.55-5.27) and 1.62 (0.52-5.02), respectively. Rates of all @entity5 were not significantly different from general population rates. The relative risk (RR) of @entity5 , adjusted for age and @entity249 type, was, in the treated group compared with the untreated group, 1.11 (95% CI 0.56-2.20) for @entity43 . The risk of body of @entity5 was increased in the exposed and unexposed groups combined ( @entity4093 .84 [1.18-6.81]). @entity1 with @entity249 , independent of @entity52 exposure, had significantly increased risks of @entity43 (RR = 19.19 [2.23-165.0]) and body of @entity5 (RR = 6.34 [1.06-38.0]) compared with @entity1 with known causes of @entity249 . This relatively short-term follow-up suggests that ovarian stimulation with @entity52 is not associated with an increased risk of @entity0 . Although there was no significantly increased risk of @entity43 after ovarian stimulation with @entity52 the small number of cases limits the conclusions that can be drawn. Longer-term follow-up of large cohorts of @entity1 who have been in @entity52 programmes will be necessary.
